23:35 , Nov 20, 2018 |  BC Extra  |  Company News

Merck KGaA, Palantir team up to drive cancer research data sharing and integration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
00:53 , Nov 20, 2018 |  BC Extra  |  Clinical News

Bavencio fails Phase III for ovarian cancer

Hopes for Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) to get ahead in the ovarian cancer space, where no PD-1/PD-L1 inhibitors are approved, were delayed Monday after the partners reported that PD-L1 inhibitor Bavencio avelumab...
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
03:17 , Nov 17, 2018 |  BioCentury  |  Product Development

Rethinking RECIST for immunotherapies

Momentum is growing for new tumor response criteria that better reflect the benefits of cancer immunotherapies, with FNIH, companies and FDA all pushing for validation of these criteria. At a Nov. 9 workshop co-hosted by...
20:42 , Nov 16, 2018 |  BC Extra  |  Clinical News

Imfinzi fails again in MYSTIC trial for first-line NSCLC

In another strike against tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination with PD-L1 inhibitor Imfinzi durvalumab missed the co-primary endpoint of improving overall survival (OS) in the Phase III MYSTIC trial...
19:59 , Nov 16, 2018 |  BioCentury  |  Tools & Techniques

Benchtop manufacturing gets smaller

Publisher’s note: This story originally ran in the Nov. 15, 2018 issue of...
17:27 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Keytruda meets OS endpoint for second-line esophageal cancer

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab as monotherapy met the primary endpoint of improving overall survival (OS) vs. investigator's choice of chemotherapy in the Phase III KEYNOTE-181 trial as second-line treatment of advanced...
16:02 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Nektar makes case for NKTR-214 optimism

On a Nov. 10 call with investors, Nektar Therapeutics (NASDAQ:NKTR) and a PI for the Phase I/II PIVOT-2 trial highlighted differences in patient demographics that could be critical for NKTR-214 plus Opdivo nivolumab to achieve...
15:56 , Nov 16, 2018 |  BC Week In Review  |  Financial News

M Ventures leads $30M series A for RNA start-up Ribometrix

RNA company Ribometrix Inc. (Durham, N.C.) raised $30 million in a series A round led by M Ventures on Nov. 13. Fellow new investors Amgen Ventures, Pappas Capital and Illumina Ventures also participated, as did...
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...